Closing Remarks on the Future Treatment Landscape of Myelofibrosis

EP: 1.Overview of Myelofibrosis Types and Presentations

EP: 2.Myelofibrosis: Molecular Pathways and Prognostic Factors

EP: 3.Approved Therapies for Myelofibrosis

EP: 4.Potential Role of Momelotinib in Myelofibrosis

EP: 5.Treatment Sequencing Considerations in Myelofibrosis

EP: 6.Emerging Research in Myelofibrosis Treatment

Now Viewing

EP: 7.Closing Remarks on the Future Treatment Landscape of Myelofibrosis

Transcript:

Aaron Gerds, MD, MS: I have to say that I’m absolutely excited in anticipation of the new developments in myelofibrosis and in the care of these patients. There are certainly challenges given patients’ ages and comorbidities at the time of diagnosis, as well as the cytopenias that accompany this disease and the significant disease burden this entity wages upon patients. It’s absolutely exciting now to have 3 approved JAK inhibitors with potentially a fourth in the near future, and with a number of large prospective phase 3 trials about to read out in the next couple of years. Even further on the horizon, we’ve got all these new and interesting therapies being developed that are very creative and hitting the disease in very different ways, and so I would say this is an incredibly exciting time to be in the field.

For folks practicing in the communities and seeing these patients on occasion, with all these rapid changes in the disease landscape and treatment landscape for myelofibrosis, partnering with a center of excellence or someone who’s deep into the care of patients with myelofibrosis can be invaluable. There are a lot of subtleties that are now emerging with multiple therapies being available. Weeding through all those subtleties on a patient-by-patient basis is incredibly challenging for someone like myself who does this all the time. I can’t imagine how difficult it would be for a general oncologist practicing in the community setting. Certainly, I highly encourage partnering with myelofibrosis experts, if you will, to navigate this rapidly changing field because this is the time. This is an incredibly exciting time, things are changing; new therapies are being approved at an incredible rate. We can foresee a future not too distant where this is like myeloma or breast cancer, where there are tons of options, and I think guidance will be needed to help navigate these new advancements.

Transcript edited for clarity.